GLP-1 receptor agonists and cardiovascular risk in routine clinical practice
Lancet Diabetes Endocrinol
.
2019 Feb;7(2):78-80.
doi: 10.1016/S2213-8587(18)30340-1.
Epub 2018 Dec 5.
Authors
Guntram Schernthaner
1
,
Marie Helene Schernthaner-Reiter
2
Affiliations
1
Department of Medicine I, Rudolfstiftung Hospital, 1030 Vienna, Austria. Electronic address: guntram.schernthaner@meduniwien.ac.at.
2
Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
PMID:
30527908
DOI:
10.1016/S2213-8587(18)30340-1
No abstract available
Publication types
Comment
MeSH terms
Cardiovascular Diseases*
Cohort Studies
Denmark
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents
Liraglutide*
Risk Factors
Sweden
Substances
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Liraglutide